Cargando…

Clinical use of FLT3 inhibitors in acute myeloid leukemia

Acute myeloid leukemia (AML) is a highly heterogeneous disease. Mutation with internal tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most common driver mutations and the presence of FLT3-ITD delivers poor prognosis. A number of ongoing clinical efforts are focused on...

Descripción completa

Detalles Bibliográficos
Autores principales: Sutamtewagul, Grerk, Vigil, Carlos E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198878/
https://www.ncbi.nlm.nih.gov/pubmed/30410361
http://dx.doi.org/10.2147/OTT.S171640
_version_ 1783365034309582848
author Sutamtewagul, Grerk
Vigil, Carlos E
author_facet Sutamtewagul, Grerk
Vigil, Carlos E
author_sort Sutamtewagul, Grerk
collection PubMed
description Acute myeloid leukemia (AML) is a highly heterogeneous disease. Mutation with internal tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most common driver mutations and the presence of FLT3-ITD delivers poor prognosis. A number of ongoing clinical efforts are focused on FLT3 inhibitor use to improve the outcomes of this otherwise difficult leukemia. Midostaurin has been shown to improve outcomes in FLT3-mutated AML in the frontline setting. Several FLT3 inhibitors, especially second-generation agents, have shown clinically meaningful activity in relapsed or refractory AML and in patients not amenable to intensive therapy. In this article, we briefly review the biology of FLT3 in the physiological state and its role in leukemogenesis. We present a detailed review of current clinical evidence of FLT3 inhibitors and their use in the induction, treatment of relapsed or refractory disease, and maintenance setting.
format Online
Article
Text
id pubmed-6198878
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61988782018-11-08 Clinical use of FLT3 inhibitors in acute myeloid leukemia Sutamtewagul, Grerk Vigil, Carlos E Onco Targets Ther Review Acute myeloid leukemia (AML) is a highly heterogeneous disease. Mutation with internal tandem duplication of fms-like tyrosine kinase-3 (FLT3-ITD) is one of the two most common driver mutations and the presence of FLT3-ITD delivers poor prognosis. A number of ongoing clinical efforts are focused on FLT3 inhibitor use to improve the outcomes of this otherwise difficult leukemia. Midostaurin has been shown to improve outcomes in FLT3-mutated AML in the frontline setting. Several FLT3 inhibitors, especially second-generation agents, have shown clinically meaningful activity in relapsed or refractory AML and in patients not amenable to intensive therapy. In this article, we briefly review the biology of FLT3 in the physiological state and its role in leukemogenesis. We present a detailed review of current clinical evidence of FLT3 inhibitors and their use in the induction, treatment of relapsed or refractory disease, and maintenance setting. Dove Medical Press 2018-10-16 /pmc/articles/PMC6198878/ /pubmed/30410361 http://dx.doi.org/10.2147/OTT.S171640 Text en © 2018 Sutamtewagul and Vigil. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Sutamtewagul, Grerk
Vigil, Carlos E
Clinical use of FLT3 inhibitors in acute myeloid leukemia
title Clinical use of FLT3 inhibitors in acute myeloid leukemia
title_full Clinical use of FLT3 inhibitors in acute myeloid leukemia
title_fullStr Clinical use of FLT3 inhibitors in acute myeloid leukemia
title_full_unstemmed Clinical use of FLT3 inhibitors in acute myeloid leukemia
title_short Clinical use of FLT3 inhibitors in acute myeloid leukemia
title_sort clinical use of flt3 inhibitors in acute myeloid leukemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198878/
https://www.ncbi.nlm.nih.gov/pubmed/30410361
http://dx.doi.org/10.2147/OTT.S171640
work_keys_str_mv AT sutamtewagulgrerk clinicaluseofflt3inhibitorsinacutemyeloidleukemia
AT vigilcarlose clinicaluseofflt3inhibitorsinacutemyeloidleukemia